7,580.07

-140.32

-1.82%

51,770.31

-572.25

-1.09%

25,437.00

-747.73

-2.86%

2,811.84

-47.37

-1.66%

4.9290

-0.0600

-1.20%

19.42

+2.22

+12.91%

3,884.90

-146.50

-3.63%

77,143.96

-872.99

-1.12%

Crude Oil Dec 26

102.95

+0.95

+0.93%

US Private Equity

10,850.63

-82.20

-0.75%

NasdaqCM - Delayed Quote USD

ImmuCell Corporation (ICCC)

10.26 -0.28 (-2.69%)

At close: October 30 at 4:00:00 PM EDT

Loading Chart for ICCC

Chart Range Bar

Interval:

In partnership with ChartIQ

ImmuCell Announces a 46% Increase in Product Sales in Quarter Three of 2026, Based on Preliminary, Unaudited Sales Results

ImmuCell Announces a 46% Increase in Product Sales in Quarter Three of 2026, Based on Preliminary, Unaudited Sales Results

ImmuCell (ICCC) Q2 2026 Earnings Call Transcript

ImmuCell (ICCC) Q2 2026 Earnings Call Transcript

ImmuCell Corp (ICCC) (Q2 2026) Earnings Call Highlights: Record Net Income and Market Share ...

ImmuCell Corp (ICCC) (Q2 2026) Earnings Call Highlights: Record Net Income and Market Share ...

ImmuCell Q2 Earnings Call Highlights

ImmuCell Q2 Earnings Call Highlights

ImmuCell Announces Unaudited Financial Results for the Quarter Ended June 30, 2026

ImmuCell Announces Unaudited Financial Results for the Quarter Ended June 30, 2026

ImmuCell to Announce Unaudited Financial Results for the Quarter Ended June 30, 2026

ImmuCell to Announce Unaudited Financial Results for the Quarter Ended June 30, 2026

ImmuCell Posts Strong Preliminary Q2 Sales on U.S. Demand

ImmuCell Posts Strong Preliminary Q2 Sales on U.S. Demand

ImmuCell Announces a 12% Increase in Product Sales in Q2 of 2026 and a 21% Increase in the First Six Months of 2026, Based on Preliminary, Unaudited Sales Results

ImmuCell Announces a 12% Increase in Product Sales in Q2 of 2026 and a 21% Increase in the First Six Months of 2026, Based on Preliminary, Unaudited Sales Results

ICCC's Valuation Remains Premium: Is it Worth Overpaying for?

ICCC's Valuation Remains Premium: Is it Worth Overpaying for?

ImmuCell Q1 Earnings Rise Y/Y as Sales Climb on Strong Demand

ImmuCell Q1 Earnings Rise Y/Y as Sales Climb on Strong Demand

ImmuCell Corp (ICCC) Q1 2026 Earnings Call Highlights: Record Revenue and Strategic Growth

ImmuCell Corp (ICCC) Q1 2026 Earnings Call Highlights: Record Revenue and Strategic Growth

Mobilize your Website

View Site in Mobile | Classic

Share by: